EUVIMEDEUVIMED entdecken
Crossref

A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome

Marjan Mokhtare, Maryam Fathi, Amir M Sadeghian, Mohammad-Javad Sotoudeheian, Abolfazl Namazi

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01403-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Marjan Mokhtare und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Internal Medicine Department, School of Medicine, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Niya…. Hauptthemen laut MEDLINE: Rifaximin, Irritable Bowel Syndrome, Quality of Life, Diarrhea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifaximinIrritable Bowel SyndromeQuality of LifeDiarrheaHumansPilot ProjectsFemaleMaleAdultMiddle AgedSeverity of Illness IndexGastrointestinal AgentsTreatment OutcomeYoung Adult

Substanzen

RifaximinGastrointestinal Agents

Autor:innen und Institutionen

  • Gastroenterology and Hepatology, Internal Medicine Department, School of Medicine, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Niyayesh St., Sattarkhan Ave., Tehran, Iran. marjanmokhtare@yahoo.com.
  • Gastroenterology and Hepatology, Internal Medicine Department, School of Medicine, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Niyayesh St., Sattarkhan Ave., Tehran, Iran.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Mokhtare, M., Fathi, M., Sadeghian, A. M., Sotoudeheian, M. J., & Namazi, A. (2024). A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01403-w

Vancouver

Mokhtare M, Fathi M, Sadeghian AM, Sotoudeheian MJ, Namazi A. A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01403-w

BibTeX
@article{Mokhtare2024,
  author = {Mokhtare, Marjan and Fathi, Maryam and Sadeghian, Amir M and Sotoudeheian, Mohammad-Javad and Namazi, Abolfazl},
  title = {A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01403-w}
}
Kostenlos starten →